MS
RARX

Maven Securities’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Maven Securities’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-45,827
Closed -$2.15M – 477
2019
Q4 		$2.15M Buy
+45,827
New +$2.03M 0.19% 100

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maven Securities's RARX Position: Q1 2020 in Review

Maven Securities sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 45,827 shares — an estimated $2.15M sold.

Maven Securities first reported a position in RARX in Q4 2019 and held it in 1 quarter. The position peaked at $2.15M in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

  • Maven Securities reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Maven Securities sold 45,827 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $2.15M.
  • Maven Securities first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Maven Securities's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.15M in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Maven Securities's 13F filing for Q1 2020, filed 15 May 2020.